Symbols

KMTS

Kestra Medical·NASDAQ

--(--)

KMTS fundamentals

KMTS Q3 2026 Earnings

Kestra Medical (KMTS) released its earnings on Mar 17, 2026: revenue was 24.55M (YoY +62.70%), beat estimates; EPS was -0.61 (YoY +51.20%), missed estimates.

Revenue / YoY

24.55M

+62.70%

EPS / YoY

-0.61

+51.20%

Report date

Mar 17, 2026

KMTS Earnings Call Summary for Q3,2026

Revenue Acceleration: Q3 2026 revenue up 63% YoY to $24.6M, with 58% prescription growth and 900+ new patients.
Gross Margin Expansion: 52.6% (up 900bps YoY), targeting 70%+ with scale.
Market Leadership: WCD market growing 15%+ vs 8% 12 months ago, with Kestra adding 50+ new sales reps.
Strategic Innovations: FDA-approved algorithm update reduces false alarms; Biobeat ABPM integration for 72% of ACE-PAS patients.
Reimbursement Wins: Florida Medicaid contracts, VA federal supply schedule, and 2% Medicare rate increase.
Operational Efficiency: 80%+ in-network rate, 46% conversion rate (vs 43% prior), and $9M Q3 CapEx for inventory growth.

Earnings

EPS

Revenue

Revenue & Expenses

KMTS has released its 2026 Q3 earnings report, with revenue of 24.55M, reflecting a YoY change of 62.70%, and net profit of -34.17M, showing a YoY change of -57.02%. The Sankey diagram below clearly presents KMTS's revenue sources and cost distribution.

Key Indicators

Kestra Medical (KMTS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Kestra Medical (KMTS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Kestra Medical (KMTS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Kestra Medical (KMTS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown